New Treatments for Cancer
Immunotherapy, CAR-T cell therapy, and vaccines are three new treatments for cancer that have been developed over the last decade. Immunotherapy works by taking away the shield from cancer cells so that the body’s natural immune system can attack them. CAR-T cell therapy involves taking blood from patients, separating out T-cells, genetically engineering them to be more robust, and then reintroducing them into the body. Vaccines also stimulate the body’s natural defense system by forming an antibody response. Drug development is traditionally a lengthy process, but in the future, omics technologies will help target drugs more precisely and quickly.
New Drugs for Cancer Patients
Patients with cancer have the potential to benefit from new drugs, such as antibody-drug conjugates, that are more effective than traditional treatments. Additionally, real world evidence and data is being used to create advanced clinical trial designs, such as basket and umbrella trials, that can optimize the efficacy of these drugs. These trials are also using biomarker stratification to identify which patients will most likely benefit from a particular drug.
Transforming Outcomes of Patients with Cancer
In cancer care, drugs are transforming the outcomes of patients and leading to more quality of life. Real world evidence and virtual competitor arm strategies have been used to increase the number of patients given the experimental drug rather than the control drug. Genomic testing is also improving the precision of treatments for different types of cancer. AI will help bridge gaps in clinical trials by enrolling more minorities into trials.
Changes in Oncology
In the last two decades, there have been many changes in oncology including a decrease in cancer mortality by 10% every decade. This is due to advances in screening, genomics, immunotherapy, artificial intelligence and drug discovery. Real world evidence is still difficult to extract from mixed source data, but it can be improved with standardized templates and minimal variance. Additionally, more treatments are becoming available for later lines of treatment as targeted agents are less damaging to patients.
Note: This is an AI generated transcript, not edited by a staff writer and is solely intended for educational purposes. If you have any questions/concerns, reach out to events@beckershealthcare.com
This panel was live on 04/05/2023 at the event listed here.
If you are interested in event like this, you can visit our Upcoming Conferences.
